Bhopal gas victims allege that they are being used as guinea pigs for unethical drug trials without being informed.An RTI has revealed that Bhopal Memorial Hospital has pocketed over Rs 1 crore by allowing pharma companies to conduct clinical trials on disaster victims.Shankar Lal was 33 when the Bhopal Union Carbide leak of 1984 happened. Lal and his pregnant wife Laxmi survived but not their child who died at birth....

The Bhopal Memorial Hospital and Research Centre (BMHRC) has pocketed over Rs 1 crore by allowing pharma companies to conduct clinical trials of drugs on its patients — victims of the gas disaster of 1984. Shockingly, out of the 7 trials carried out in the hospital since 2004, only one was inspected or monitored by the government watchdog Drug Controller General of India (DCGI). This was revealed in response to...

India may have to abide by a series of international standards and regulatory practices in the healthcare sector, if it agrees to some proposals that are part of the ongoing India–EU Free Trade Agreement (FTA) negotiations. For instance, EU negotiators have sought India’s commitment to adopting Global Harmonization Task Force (GHTF) norms for medical devices. The move comes at a time when India and other Asian countries are trying to formulate...

Said it failed to state ethical aspects involved in the study Proposal was based on the assumption that vaccine was safe and efficacious: PHFI Brinda demands compensation for all subjects victimised by vaccine programme The proposal for conducting the now controversial “Post-licensure observational study of Human Papilloma Virus (HPV) vaccination: Demonstration Project,” carried out by a non-governmental organisation PATH for two major pharmaceutical companies, had been turned down by the Public Health Foundation...

Rules out blanket ban on or approval of such studies ‘HPV vaccination should supplement cervical cancer screening programme' The three-member committee, set up to probe the alleged irregularities in conducting studies using human papillomavirus (HPV) vaccine by PATH in India, has identified several deficiencies in the planning and implementation of the project leading “to a crisis requiring suspension of the study,” but has fallen short of fixing responsibility on any individual or...